Professor Reinhard Dummer is Professor of the University of Zurich and Vice-Chairman of the Department of Dermatology in the University Hospital of Zürich, Switzerland and is a key thought leader in worldwide cutaneous oncology. Currently he is heading of the Skin Cancer Unit and the Clinical Trial Unit of the Department of Dermatology. Professor Dummer began his medical education in hematology and oncology before successfully completing his dermatology residency in Würzburg, Germany, and Zürich in 1992. He is Board Certified in allergology, clinical immunology, dermatology and dermatopathology.
Professor Dummer’s principal research interests are molecular biology, immunology and immunotherapy of cutaneous malignancies, including cutaneous lymphomas and melanomas. He has published more than 741 papers with a cumulative impact factor of more than 6372. He was past-president of the Melanoma Project Group of the Swiss Institute for Applied Cancer Research since 1999 -2016, is a member of German National Academy of Sciences (Leopoldina) and is past board member of the Society for Melanoma Research and past President of the International Society for Cutaneous Lymphomas. He is a founding and board member of the European Association of Dermato-Oncology (EADO), ESMO, URPP and past President of the European Society for Dermatological Research (ESDR).
In the last 20 years, he has developed a leading skin cancer center. This center offers best medical care, a network of clinical trials reaching from phase I to phase III. His contributions are acknowledge in many publications in outstanding journals such as New England Journal of Medicine, Lancet, Lancet Oncology, Press etc. Locally he is intensify cooperation with basic research group at the University and the federal University (ETH). This has resulted in translation work improving our understanding of cutaneous malignancies.
Jerrold M. Olefsky, MD, is Professor of Medicine at the University of California, San Diego (UCSD) Division of Endocrinology and Metabolism and the Associate Dean of Scientific Affairs for the UCSD School of Medicine. His work has been instrumental in defining the basic genetic and cellular mechanisms responsible for the pathogenesis of Type II Diabetes, metabolic syndrome, and other diseases. Dr. Olefsky is a member of the Institute of Medicine and was the 1998 recipient of the American Diabetes Association’s Banting Medal for Scientific Achievement.
Dr. Arun Sanyal is a specialist in chronic liver disease and its outcomes. He is the Executive Director, Education Core, Clinical Center for Translational Research at Virginia Commonwealth University. He previously served as a Chair of the National Institutes of Health (NIH) NASH Research Network and is the current Chair of the Liver Study Section at NIH. He is also the Academic and Steering Committee Co-Chair of The Liver Forum. His research into liver diseases has led to recommendations related to variceal hemorrhage, ascites, hepatorenal syndrome, hepatic encephalopathy and NASH. Over the past 10 years, his research interests have focused on clinical studies on nonalcoholic fatty liver disease (NAFLD), the role of the microbiome in NAFLD and nonalcoholic steatohepatitis (NASH) and the development of effective therapies.
R. Balfour Sartor, MD, is the Midgette Distinguished Professor of Medicine, Microbiology & Immunology, and Co-Director of the UNC Multidisciplinary Center for IBD Research and Treatment. He is a nationally and internationally recognized authority on mucosal immunology and inflammatory bowel disease. His research focuses on better defining mechanisms of chronic intestinal inflammation, mucosal homeostasis and identifying new areas for therapeutic intervention for patients with inflammatory bowel disease. His lab investigates the ability of specific components of the intestinal microbiota to induce chronic T-cell mediated inflammation in genetically susceptible hosts as compared to a protective mucosal immune response in normal hosts. Additional studies explore the ability for dietary products to modify the composition and function of intestinal microbiota. Recent work has extended these microbial-host interactions to analysis of human samples, comparing healthy subjects to both Crohn's disease and ulcerative colitis patients. Dr. Sator is currently the Chief Medial Advisor to the Crohn's and Colitis Foundation of America (CCFA).